200 related articles for article (PubMed ID: 35740106)
1. Biochemical Discrimination of the Down Syndrome-Related Metabolic and Oxidative/Nitrosative Stress Alterations from the Physiologic Age-Related Changes through the Targeted Metabolomic Analysis of Serum.
Lazzarino G; Amorini AM; Mangione R; Saab MW; Di Stasio E; Di Rosa M; Tavazzi B; Lazzarino G; Onder G; Carfì A
Antioxidants (Basel); 2022 Jun; 11(6):. PubMed ID: 35740106
[TBL] [Abstract][Full Text] [Related]
2. Metabolic and Growth Rate Alterations in Lymphoblastic Cell Lines Discriminate Between Down Syndrome and Alzheimer's Disease.
Coskun P; Helguera P; Nemati Z; Bohannan RC; Thomas J; Samuel SE; Argueta J; Doran E; Wallace DC; Lott IT; Busciglio J
J Alzheimers Dis; 2017; 55(2):737-748. PubMed ID: 27802222
[TBL] [Abstract][Full Text] [Related]
3. Serum MHPG strongly predicts conversion to Alzheimer's disease in behaviorally characterized subjects with Down syndrome.
Dekker AD; Coppus AM; Vermeiren Y; Aerts T; van Duijn CM; Kremer BP; Naudé PJ; Van Dam D; De Deyn PP
J Alzheimers Dis; 2015; 43(3):871-91. PubMed ID: 25125467
[TBL] [Abstract][Full Text] [Related]
4. Plasma metabolites related to cellular energy metabolism are altered in adults with Down syndrome and Alzheimer's disease.
Gross TJ; Doran E; Cheema AK; Head E; Lott IT; Mapstone M
Dev Neurobiol; 2019 Jul; 79(7):622-638. PubMed ID: 31419370
[TBL] [Abstract][Full Text] [Related]
5. Assessment of cognitive decline associated with aging: a comparison of individuals with Down syndrome and other etiologies.
Das JP; Mishra RK
Res Dev Disabil; 1995; 16(1):11-25. PubMed ID: 7701089
[TBL] [Abstract][Full Text] [Related]
6. Atypical aging in Down syndrome.
Zigman WB
Dev Disabil Res Rev; 2013; 18(1):51-67. PubMed ID: 23949829
[TBL] [Abstract][Full Text] [Related]
7. Differences in age-related effects on brain volume in Down syndrome as compared to Williams syndrome and typical development.
Koran ME; Hohman TJ; Edwards CM; Vega JN; Pryweller JR; Slosky LE; Crockett G; Villa de Rey L; Meda SA; Dankner N; Avery SN; Blackford JU; Dykens EM; Thornton-Wells TA
J Neurodev Disord; 2014; 6(1):8. PubMed ID: 24713364
[TBL] [Abstract][Full Text] [Related]
8. Oxidative Stress and Down Syndrome: A Route toward Alzheimer-Like Dementia.
Perluigi M; Butterfield DA
Curr Gerontol Geriatr Res; 2012; 2012():724904. PubMed ID: 22203843
[TBL] [Abstract][Full Text] [Related]
9. RCAN1 knockout and overexpression recapitulate an ensemble of rest-activity and circadian disruptions characteristic of Down syndrome, Alzheimer's disease, and normative aging.
Wong H; Buck JM; Borski C; Pafford JT; Keller BN; Milstead RA; Hanson JL; Stitzel JA; Hoeffer CA
J Neurodev Disord; 2022 May; 14(1):33. PubMed ID: 35610565
[TBL] [Abstract][Full Text] [Related]
10. Low-molecular weight compounds in human seminal plasma as potential biomarkers of male infertility.
Lazzarino G; Listorti I; Muzii L; Amorini AM; Longo S; Di Stasio E; Caruso G; D'Urso S; Puglia I; Pisani G; Lazzarino G; Tavazzi B; Bilotta P
Hum Reprod; 2018 Oct; 33(10):1817-1828. PubMed ID: 30239786
[TBL] [Abstract][Full Text] [Related]
11. Altered connectivity of the default mode network in cognitively stable adults with Down syndrome: "Accelerated aging" or a prelude to Alzheimer's disease?
Rosas HD; Lewis LR; Mercaldo ND; Nasr S; Brickman AM; Siless V; Yassa M; Sathishkumar M; Lott I; Schupf N; Silverman W; Lai F;
Alzheimers Dement (Amst); 2021; 13(1):e12105. PubMed ID: 34027014
[TBL] [Abstract][Full Text] [Related]
12. Meta-analysis of metabolites involved in bioenergetic pathways reveals a pseudohypoxic state in Down syndrome.
Pecze L; Randi EB; Szabo C
Mol Med; 2020 Nov; 26(1):102. PubMed ID: 33167881
[TBL] [Abstract][Full Text] [Related]
13. Neurological phenotypes for Down syndrome across the life span.
Lott IT
Prog Brain Res; 2012; 197():101-21. PubMed ID: 22541290
[TBL] [Abstract][Full Text] [Related]
14. Association between frontal cortex oxidative damage and beta-amyloid as a function of age in Down syndrome.
Cenini G; Dowling AL; Beckett TL; Barone E; Mancuso C; Murphy MP; Levine H; Lott IT; Schmitt FA; Butterfield DA; Head E
Biochim Biophys Acta; 2012 Feb; 1822(2):130-8. PubMed ID: 22009041
[TBL] [Abstract][Full Text] [Related]
15. Metabolomic analysis for first-trimester Down syndrome prediction.
Bahado-Singh RO; Akolekar R; Mandal R; Dong E; Xia J; Kruger M; Wishart DS; Nicolaides K
Am J Obstet Gynecol; 2013 May; 208(5):371.e1-8. PubMed ID: 23313728
[TBL] [Abstract][Full Text] [Related]
16. Bile acid synthesis, modulation, and dementia: A metabolomic, transcriptomic, and pharmacoepidemiologic study.
Varma VR; Wang Y; An Y; Varma S; Bilgel M; Doshi J; Legido-Quigley C; Delgado JC; Oommen AM; Roberts JA; Wong DF; Davatzikos C; Resnick SM; Troncoso JC; Pletnikova O; O'Brien R; Hak E; Baak BN; Pfeiffer R; Baloni P; Mohmoudiandehkordi S; Nho K; Kaddurah-Daouk R; Bennett DA; Gadalla SM; Thambisetty M
PLoS Med; 2021 May; 18(5):e1003615. PubMed ID: 34043628
[TBL] [Abstract][Full Text] [Related]
17. Bidirectional Regulation of Amyloid Precursor Protein-Induced Memory Defects by Nebula/DSCR1: A Protein Upregulated in Alzheimer's Disease and Down Syndrome.
Shaw JL; Zhang S; Chang KT
J Neurosci; 2015 Aug; 35(32):11374-83. PubMed ID: 26269644
[TBL] [Abstract][Full Text] [Related]
18. Antioxidants in Down Syndrome: From Preclinical Studies to Clinical Trials.
Rueda Revilla N; Martínez-Cué C
Antioxidants (Basel); 2020 Aug; 9(8):. PubMed ID: 32756318
[TBL] [Abstract][Full Text] [Related]
19. Developmental deficits and staging of dynamics of age associated Alzheimer's disease neurodegeneration and neuronal loss in subjects with Down syndrome.
Wegiel J; Flory M; Kuchna I; Nowicki K; Wegiel J; Ma SY; Zhong N; Bobrowicz TW; de Leon M; Lai F; Silverman WP; Wisniewski T
Acta Neuropathol Commun; 2022 Jan; 10(1):2. PubMed ID: 34983655
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
